Alnoor Malick
Allergy · Houston, TXNPI 1780689679
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,954 of the $8,505 with a category attached, or 81.8%. It is spread thinly across 34 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations.
Across 354 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$805
- AstraZeneca$489
- Novartis$405
- Pfizer$395
- plus $3K from 28 others
What the payments were for
- Consulting fees$1,38016%
- Food & beverage$6,95482%
- Education$1712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 25 | $1,954 |
| GSK | 83 | $1,162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $805 |
| AstraZeneca | 27 | $489 |
| Novartis | 18 | $405 |
| Pfizer | 21 | $395 |
| Grifols USA, LLC | 17 | $300 |
| Sanofi | 11 | $290 |
| CSL Behring | 11 | $272 |
| Blueprint Medicines Corporation | 10 | $260 |
| Amgen(2 entities) | 12 | $237 |
| Biocryst US Sales Co., LLC | 2 | $234 |
| Optinose US, Inc. | 10 | $212 |
| Kaleo, Inc. | 10 | $210 |
| Alk-abello, Inc | 13 | $206 |
| Boehringer Ingelheim | 9 | $166 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $150 |
| LEO Pharma Inc. | 6 | $124 |
| Shire North American Group Inc | 6 | $121 |
| Octapharma USA, Inc. | 3 | $112 |
| Hospira, Inc. | 3 | $69 |
| Organon | 3 | $48 |
| Azurity Pharmaceuticals, Inc. | 2 | $43 |
| Ionis Pharmaceuticals, Inc. | 1 | $40 |
| Galderma Laboratories, L.p. | 2 | $33 |
| Incyte Corporation | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| MDD US Operations, LLC | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Covis Pharma GmbH | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Tersera Therapeutics LLC | 1 | $15 |
| USWM, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,505 in reported general payments places this provider in the 70th percentile of 69 allergy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $67,888 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $35,023 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $23,581 |
| Epinephrine | 62 | $11,830 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $3,283 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 14 | $2,081 |
| Azelastine Hcl | 47 | $1,596 |
| Cyclosporine ModifiedCyclosporine, Modified | 12 | $959 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $857 |
| Fluticasone Propionate | 34 | $742 |
| Montelukast Sodium | 46 | $658 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $140 |
| Methylprednisolone | 12 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,162 | $58,60575 claims |
| Hikma Pharmaceuticals USAEpinephrine | $18 | $11,83062 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $22 | $3,28311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 69 allergy providers in Texas.
Other allergy in Houston
- Carlos VitalHouston$14K
- David EnglerHouston$13K
- Aneesh AngirekulaHouston$2K
- Phung NguyenHouston$834
- Gary GrossDallas$602K
- Rene LeonSouthlake$48K
- Christina HuddlestonDallas$26K
- Alireza ShakouriSouthlake$17K
- Zachary MarshallRoanoke$17K
- Stuart AbramsonSan Angelo$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.